title: Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant.
abstract: The nucleoprotein (NP) of influenza viruses is highly conserved and therefore has become one of the major targets of current universal influenza vaccine (UIV) studies. In this study, the recombinant nucleoprotein (NP) of the A/PR/8/34 (H1N1) influenza virus strain was expressed using an Escherichia coli (E. coli) expression system and then purified as a candidate UIV. The NP protein was administered intranasally or intraperitoneally twice at 3-week intervals to female BALB/c mice in combination with C48/80 adjuvant. Then, the mice were challenged with homologous or heterologous influenza viruses at a lethal dose 3 weeks after the last immunization. The results showed that the serum IgG titers of all of the mice immunized with NP reached a higher level and the protection provided by NP vaccine against the homologous virus depended on the administered dosage and adjuvant. In addition, immunization with 100 μg NP in combination with C48/80 adjuvant could provide good cross-protection against heterologous H9N2 avian influenza viruses. This study indicated that NP as a candidate antigen of UIV immunized intranasally could effectively induce mucosal and cell-mediated immunity, with the potential to control epidemics caused by the appearance of new emerging influenza viruses.
authors.affiliation: a Shanghai Institute of Biological Products ; Shanghai , China.
authors.forename: Mei
authors.initials: M
authors.lastname: Zheng
authors.forename: Fen
authors.initials: F
authors.lastname: Liu
authors.forename: Yiqing
authors.initials: Y
authors.lastname: Shen
authors.forename: Shilei
authors.initials: S
authors.lastname: Wang
authors.forename: Wenting
authors.initials: W
authors.lastname: Xu
authors.forename: Fang
authors.initials: F
authors.lastname: Fang
authors.forename: Bing
authors.initials: B
authors.lastname: Sun
authors.forename: Zhenyuan
authors.initials: Z
authors.lastname: Xie
authors.forename: Ze
authors.initials: Z
authors.lastname: Chen
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000281:Administration, Intranasal; D000818:Animals; D056738:Cross Protection; D004195:Disease Models, Animal; D005260:Female; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D053127:Influenza A Virus, H9N2 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007274:Injections, Intraperitoneal; D008807:Mice, Inbred BALB C; D019590:Nucleocapsid Proteins; D009976:Orthomyxoviridae Infections / Q000517:prevention & control / Q000821:virology; D016601:RNA-Binding Proteins / Q000008:administration & dosage / Q000276:immunology*; D016019:Survival Analysis; D014611:Vaccination / Q000379:methods; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014758:Viral Core Proteins / Q000008:administration & dosage / Q000276:immunology*; D003189:p-Methoxy-N-methylphenethylamine / Q000008:administration & dosage*
chemical_list: D000276:Adjuvants, Immunologic; D007252:Influenza Vaccines; C048842:NP protein, Influenza A virus; D019590:Nucleocapsid Proteins; D016601:RNA-Binding Proteins; D014614:Vaccines, Synthetic; D014758:Viral Core Proteins; D003189:p-Methoxy-N-methylphenethylamine
keywords: compound 48/80; influenza; intranasal immunization; mucosal adjuvant; nucleoprotein